Elsilimomab
Based on 1 Customer Validation
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.44%
- CAS No.: 468715-71-1
- 분자량:145.96 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
|
IL-6 1.4 nM (IC50) |
Elsilimomab specifically inhibits IL-6 but not LIF (leukemia inhibitory factor)-induced cell growth[2].
Elsilimomab (20 μg/mL) neutralizes human IL-6[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Murine B9 cells
-
Concentration:20 μg/mL
-
Incubation Time:3 days
-
Result:B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IL-6 Protein, Human can bind Elsilimomab. The EC50 for this effect is 32.74 ng/mL. -
Flow cytometric analysis of 1.5×106 Siha cells labeling Elsilimomab (HY-P99287, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 468715-71-1
-
Appearance Liquid
-
분자량 145.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Elsilimomab]
-
Synonyms
B-E8; Anti-IL-6 MAB B-E8
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (259 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265. [Content Brief]
[2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390. [Content Brief]
[3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)